Search research articles
Contact Us
Filters
Showing results (191-200 of 293) with videos related to
Page
of 30
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2020
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors
Martine J Piccart, Florentine S Hilbers, Judith M Bliss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2011
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib
Patrick G Morris, Carol Chen, Richard Steingart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2012
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101
Lawrence N Shulman, Constance T Cirrincione, Donald A Berry, et al.
Clinical Breast Cancer
|
October 28, 2008
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible
Chau Dang, Gabriella D'Andrea, Diana Lake, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2009
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction
Patrick G Morris, Maura Dickler, Heather L McArthur, et al.
NPJ Breast Cancer
|
March 23, 2022
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
Emanuela Ferraro, Jasmeet Singh, Sujata Patil, et al.
The Oncologist
|
February 8, 2017
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience
Jasmeet C Singh, Anita Mamtani, Andrea Barrio, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 5, 2016
Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology
Paul S Weisman, Charlotte K Y Ng, Edi Brogi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2014
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Chau Dang, Neil Iyengar, Farrah Datko, et al.
The Journal of Pathology
|
December 8, 2016
The genetic landscape of breast carcinomas with neuroendocrine differentiation
Caterina Marchiò, Felipe C Geyer, Charlotte Ky Ng, et al.
Page
of 30
Search research articles
Search
Showing results (191-200 of 293) with videos related to
Sort By:
Page
of 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2020
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors
Martine J Piccart, Florentine S Hilbers, Judith M Bliss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2011
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib
Patrick G Morris, Carol Chen, Richard Steingart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2012
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101
Lawrence N Shulman, Constance T Cirrincione, Donald A Berry, et al.
Clinical Breast Cancer
|
October 28, 2008
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible
Chau Dang, Gabriella D'Andrea, Diana Lake, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2009
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction
Patrick G Morris, Maura Dickler, Heather L McArthur, et al.
NPJ Breast Cancer
|
March 23, 2022
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
Emanuela Ferraro, Jasmeet Singh, Sujata Patil, et al.
The Oncologist
|
February 8, 2017
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience
Jasmeet C Singh, Anita Mamtani, Andrea Barrio, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 5, 2016
Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology
Paul S Weisman, Charlotte K Y Ng, Edi Brogi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2014
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Chau Dang, Neil Iyengar, Farrah Datko, et al.
The Journal of Pathology
|
December 8, 2016
The genetic landscape of breast carcinomas with neuroendocrine differentiation
Caterina Marchiò, Felipe C Geyer, Charlotte Ky Ng, et al.
Page
of 30